Valeant Pharmaceuticals International Stock Price, News & Analysis (NYSE:VRX)

$14.69 0.35 (2.44 %)
(As of 11/18/2017 03:43 AM ET)
Previous Close$14.69
Today's Range$14.78 - $14.28
52-Week Range$8.31 - $18.65
Volume10.89 million shs
Average Volume17.89 million shs
Market Capitalization$4.98 billion
P/E Ratio2.32
Dividend YieldN/A
Beta-0.4

About Valeant Pharmaceuticals International (NYSE:VRX)

Valeant Pharmaceuticals International logoValeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.


Industry, Sector and Symbol:
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Sector: Pharmaceuticals - NEC
  • Symbol: NYSE:VRX
  • Previous Symbol: NYSE:BVF
  • CUSIP: N/A
  • Web: www.valeant.com
Debt:
  • Debt-to-Equity Ratio: 4.84%
  • Current Ratio: 1.26%
  • Quick Ratio: 1.03%
Price-To-Earnings:
  • Trailing P/E Ratio: 2.32
  • Forward P/E Ratio: 3.87
  • P/E Growth: 0.39
Sales & Book Value:
  • Annual Sales: $9.674 billion
  • Price / Sales: 0.53
  • Cash Flow: $14.54 per share
  • Price / Cash: 1.01
  • Book Value: $15.55 per share
  • Price / Book: 0.94
Profitability:
  • Trailing EPS: $3.90
  • Net Income: ($2,409,000,000.00)
  • Net Margins: 15.35%
  • Return on Equity: 51.56%
  • Return on Assets: 5.14%
Misc:
  • Employees: 21,500
  • Outstanding Shares: 348,590,000
 

Frequently Asked Questions for Valeant Pharmaceuticals International (NYSE:VRX)

What is Valeant Pharmaceuticals International's stock symbol?

Valeant Pharmaceuticals International trades on the New York Stock Exchange (NYSE) under the ticker symbol "VRX."

How were Valeant Pharmaceuticals International's earnings last quarter?

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) issued its earnings results on Tuesday, August, 9th. The specialty pharmaceutical company reported $1.40 earnings per share for the quarter, missing the Zacks' consensus estimate of $1.48 by $0.08. The specialty pharmaceutical company earned $2.42 billion during the quarter, compared to analyst estimates of $2.47 billion. Valeant Pharmaceuticals International had a net margin of 15.35% and a return on equity of 51.56%. The company's revenue for the quarter was down 11.4% compared to the same quarter last year. During the same period in the prior year, the business posted $2.14 EPS. View Valeant Pharmaceuticals International's Earnings History.

Where is Valeant Pharmaceuticals International's stock going? Where will Valeant Pharmaceuticals International's stock price be in 2017?

19 equities research analysts have issued 1 year target prices for Valeant Pharmaceuticals International's shares. Their forecasts range from $7.00 to $45.00. On average, they expect Valeant Pharmaceuticals International's stock price to reach $17.33 in the next twelve months. View Analyst Ratings for Valeant Pharmaceuticals International.

What are Wall Street analysts saying about Valeant Pharmaceuticals International stock?

Here are some recent quotes from research analysts about Valeant Pharmaceuticals International stock:

  • 1. According to Zacks Investment Research, "Once an acquisition giant, Valeant has been caught up in various controversies due to price hike of specialty drugs, erroneous financial reporting and termination of contracts with Philidor Rx Services. After a tumultuous period, Valeant started a rebuilding process with its new CEO, Joseph C. Papa. Even though it is still early to comment on the rebuilding process, but the company’s efforts to sell non-core assets and pay down huge levels of debt is commendable. The company reduced its debt by $4.8 billion and expects to meet its target of $5 billion debt reduction ahead of schedule. The GI business continues to struggle with weak sales of Xifaxan but should see gain in market share with an increased sales force. Valeant trimmed its guidance due to recent divestitures. However, weakness in the dermatology business persists. Shares have underperformed the industry." (10/12/2017)
  • 2. Cantor Fitzgerald analysts commented, "Valeant announced that the FDA confirmed it intends to issue a Voluntary Action Indicated (VAI) inspection classification for its Bausch + Lomb manufacturing facility in Tampa, Florida." (8/16/2017)
  • 3. Royal Bank Of Canada analysts commented, "We have revised our outlook due to the recent VRX financing and accounting treatment for Siliq revenues. While our revenue forecasts have increased due to Siliq, Adj. EBITDA forecasts have declined slightly. Following a modest increase in net debt, our price target declines to $18." (3/23/2017)
  • 4. Deutsche Bank AG analysts commented, "Lowered EPS on higher op ex, interest expense We updated our model following the company's 4Q results and 10-K filing, our meetings with management last week, and to reflect preliminary assumptions for the planned debt refinancing. Overall, we lowered our EPS estimates based primarily on higher spending and interest expense assumptions (see below), which reduced our DCF-derived PT to $19 (from $20). While our target implies material upside from the current stock price, we are sticking with our Hold rating pending greater visibility on improved demand trends for Xifaxan and other core assets, stabilization of the Dermatology business, and further steps to address the debt load and strengthen the balance sheet. We are encouraged that the company has begun to deliver on the expectations that it has set (as of 4Q), a theme we hope to see continue in the quarters ahead." (3/7/2017)
  • 5. Mizuho analysts commented, "The company is using its recently closed sale of assets to L'Oreal to repay $1.1B of a ~2.8% Term A loan due in 2018 (already excluded from our interest rate calculations). The company plans to refinance its existing credit agreement, issue new Term B loans that extend the maturity of current Term B loans due before 2022 (~$4.3B), issue new secured debt, and repay its remaining Term A loan due in April 2020 ($658M). Valeant also plans to repay a portion of its 6.75% secured debt due in 2018 (current balance is $1.59B). In tandem with this exercise, Valeant plans to relax its maintenance covenants in the revolver (currently $875M) and remove the covenants from its Term B loans. While the refinancing is not surprising, it reflects the cloudy outlook on future earnings, in our view." (3/6/2017)

Are investors shorting Valeant Pharmaceuticals International?

Valeant Pharmaceuticals International saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 45,176,392 shares, an increase of 27.5% from the October 13th total of 35,426,325 shares. Based on an average trading volume of 11,549,580 shares, the short-interest ratio is presently 3.9 days. Currently, 13.3% of the company's shares are short sold.

Who are some of Valeant Pharmaceuticals International's key competitors?

Who are Valeant Pharmaceuticals International's key executives?

Valeant Pharmaceuticals International's management team includes the folowing people:

  • Joseph C. Papa, Chairman of the Board, Chief Executive Officer (Age 61)
  • Paul S. Herendeen, Chief Financial Officer, Executive Vice President (Age 61)
  • Christina Ackermann, Executive Vice President, General Counsel (Age 52)
  • Thomas J. Appio, Executive Vice President, Company Group Chairman, International (Age 55)
  • William D. Humphries, Executive Vice President, Company Group Chairman, Dermatology (Age 50)
  • Thomas W. Ross Sr, Lead Independent Director (Age 66)
  • Richard U. DeSchutter, Independent Director (Age 76)
  • Fredric N. Eshelman Pharm.D., Ph.D., Independent Director (Age 68)
  • D. Robert Hale, Independent Director (Age 32)
  • Argeris N. Karabelas Ph.D., Independent Director (Age 64)

Who owns Valeant Pharmaceuticals International stock?

Valeant Pharmaceuticals International's stock is owned by many different of institutional and retail investors. Top institutional investors include ValueAct Holdings L.P. (5.17%), Dimensional Fund Advisors LP (1.28%), Alyeska Investment Group L.P. (0.54%), Legal & General Group Plc (0.45%), Cannell Peter B & Co. Inc. (0.43%) and Swiss National Bank (365,735.11%). Company insiders that own Valeant Pharmaceuticals International stock include Argeris N Karabelas, Joseph C Papa, Paul Herendeen, Pershing Square Capital Manage, Schutter Richard U De, Thomas W Sr Ross and Valueact Capital Master Fund,. View Institutional Ownership Trends for Valeant Pharmaceuticals International.

Who sold Valeant Pharmaceuticals International stock? Who is selling Valeant Pharmaceuticals International stock?

Valeant Pharmaceuticals International's stock was sold by a variety of institutional investors in the last quarter, including Canada Pension Plan Investment Board, Alyeska Investment Group L.P., Phoenix Investment Adviser LLC, TD Asset Management Inc., Sivik Global Healthcare LLC, APG Asset Management N.V., Boothbay Fund Management LLC and Partnervest Advisory Services LLC. View Insider Buying and Selling for Valeant Pharmaceuticals International.

Who bought Valeant Pharmaceuticals International stock? Who is buying Valeant Pharmaceuticals International stock?

Valeant Pharmaceuticals International's stock was purchased by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Beach Point Capital Management LP, Commerzbank Aktiengesellschaft FI, TB Alternative Assets Ltd., Cannell Peter B & Co. Inc., Van ECK Associates Corp, Partners Value Investments LP and Legal & General Group Plc. Company insiders that have bought Valeant Pharmaceuticals International stock in the last two years include Argeris N Karabelas, Joseph C Papa, Paul Herendeen, Schutter Richard U De, Thomas W Sr Ross and Valueact Capital Master Fund,. View Insider Buying and Selling for Valeant Pharmaceuticals International.

How do I buy Valeant Pharmaceuticals International stock?

Shares of Valeant Pharmaceuticals International can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Valeant Pharmaceuticals International's stock price today?

One share of Valeant Pharmaceuticals International stock can currently be purchased for approximately $14.69.

How big of a company is Valeant Pharmaceuticals International?

Valeant Pharmaceuticals International has a market capitalization of $4.98 billion and generates $9.674 billion in revenue each year. The specialty pharmaceutical company earns ($2,409,000,000.00) in net income (profit) each year or $3.90 on an earnings per share basis. Valeant Pharmaceuticals International employs 21,500 workers across the globe.

How can I contact Valeant Pharmaceuticals International?

Valeant Pharmaceuticals International's mailing address is 2150 Saint-Elzear Blvd W, LAVAL, QC H7L 4A8, Canada. The specialty pharmaceutical company can be reached via phone at +1-514-7446792 or via email at ir@valeant.com.


MarketBeat Community Rating for Valeant Pharmaceuticals International (NYSE VRX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  1,088 (Vote Outperform)
Underperform Votes:  1,009 (Vote Underperform)
Total Votes:  2,097
MarketBeat's community ratings are surveys of what our community members think about Valeant Pharmaceuticals International and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Valeant Pharmaceuticals International (NYSE:VRX)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Sell Ratings, 11 Hold Ratings, 5 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.11)
Consensus Price Target: $17.33 (17.99% upside)

Consensus Price Target History for Valeant Pharmaceuticals International (NYSE:VRX)

Price Target History for Valeant Pharmaceuticals International (NYSE:VRX)

Analysts' Ratings History for Valeant Pharmaceuticals International (NYSE:VRX)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/16/2017Deutsche Bank AGSet Price TargetHold$19.00 -> $18.00N/AView Rating Details
11/13/2017Wells Fargo & CompanyReiterated RatingSellN/AView Rating Details
11/13/2017BMO Capital MarketsBoost Price TargetMarket Perform$16.00 -> $17.00N/AView Rating Details
11/10/2017Piper Jaffray CompaniesReiterated RatingSell$12.00N/AView Rating Details
11/9/2017HC WainwrightReiterated RatingHold$17.00N/AView Rating Details
11/8/2017Royal Bank Of CanadaSet Price TargetSector Perform$18.00N/AView Rating Details
11/7/2017TD SecuritiesUpgradeHold -> Buy$20.00N/AView Rating Details
10/31/2017Cantor FitzgeraldSet Price TargetBuy$23.00N/AView Rating Details
10/3/2017Canaccord GenuityReiterated RatingHold$16.00LowView Rating Details
8/29/2017MizuhoReiterated RatingSell$8.00 -> $7.00HighView Rating Details
8/21/2017Stifel NicolausReiterated RatingBuy$45.00MediumView Rating Details
8/10/2017Rodman & RenshawReiterated RatingNeutral$17.00HighView Rating Details
8/10/2017Jefferies Group LLCReiterated RatingBuy$18.00HighView Rating Details
8/9/2017ScotiabankBoost Price TargetSector Perform$14.00 -> $16.00MediumView Rating Details
7/17/2017J P Morgan Chase & CoSet Price TargetHold$10.00LowView Rating Details
6/17/2017GuggenheimInitiated CoverageBuy$18.00HighView Rating Details
5/23/2017Barclays PLCReiterated RatingHold$20.00LowView Rating Details
5/10/2017BTIG ResearchReiterated RatingNeutralMediumView Rating Details
3/11/2017Morgan StanleyReiterated RatingEqual Weight$17.00 -> $12.00N/AView Rating Details
5/29/2016Susquehanna Bancshares IncReiterated RatingHold$105.00N/AView Rating Details
5/29/2016S&P Equity ResearchReiterated RatingBuyN/AView Rating Details
4/1/2016Citigroup Inc.Reiterated RatingBuyN/AView Rating Details
3/22/2016NomuraReiterated RatingNeutral$60.00N/AView Rating Details
3/15/2016CIBCDowngradeSector Perform -> Sector Underperform$90.00 -> $24.00N/AView Rating Details
12/21/2015Bank of America CorporationReiterated RatingBuyN/AView Rating Details
11/23/2015Maxim GroupReiterated RatingHoldN/AView Rating Details
(Data available from 11/19/2015 forward)

Earnings

Earnings History and Estimates Chart for Valeant Pharmaceuticals International (NYSE:VRX)

Earnings by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Earnings History by Quarter for Valeant Pharmaceuticals International (NYSE VRX)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/20176/30/2017$0.97$1.05$2.23 billion$2.23 billionViewListenView Earnings Details
5/9/20173/31/2017$0.87$2.80$2.17 billion$2.11 billionViewListenView Earnings Details
2/28/2017Q416$1.20$1.26$2.34 billion$2.40 billionViewListenView Earnings Details
11/8/2016Q316$1.78$1.55$2.49 billion$2.48 billionViewListenView Earnings Details
8/9/2016Q216$1.48$1.40$2.47 billion$2.42 billionViewN/AView Earnings Details
6/7/2016Q116$1.37$1.27$2.34 billion$2.37 billionViewN/AView Earnings Details
3/15/2016Q415$2.61$2.50$2.75 billion$2.80 billionViewListenView Earnings Details
10/19/2015Q315$2.68$2.74$2.06 billion$2.79 billionViewListenView Earnings Details
7/23/2015Q215$2.46$2.58$2.04 million$2.73 millionViewListenView Earnings Details
4/29/2015Q115$2.34$2.36$1.89 billion$2.20 billionViewN/AView Earnings Details
2/24/2015Q414$2.56$2.58$2.23 billion$2.28 billionViewN/AView Earnings Details
10/20/2014Q314$1.99$2.11$2.06 billion$2.06 billionViewListenView Earnings Details
7/31/2014Q214$1.91$1.91$1.06 billion$1.99 billionViewN/AView Earnings Details
5/8/2014Q114$1.72$1.76$1.04 billion$1.85 billionViewN/AView Earnings Details
2/27/2014Q413$2.06$2.15$986.30 million$2.06 billionViewN/AView Earnings Details
10/31/2013Q313$1.40$1.51$884.14 million$1.54 billionViewN/AView Earnings Details
8/7/2013Q213$1.28$1.34$820.09 million$1.10 billionViewN/AView Earnings Details
5/2/2013Q113$1.25$1.30$1.04 billion$1.07 billionViewN/AView Earnings Details
2/28/2013Q412$1.21$1.34$654.17 million$946.67 millionViewN/AView Earnings Details
11/2/2012Q312$1.13$1.15$875.91 million$884.00 millionViewN/AView Earnings Details
8/2/2012$0.99$1.01ViewN/AView Earnings Details
5/3/2012$0.96$0.99ViewN/AView Earnings Details
11/3/2011$0.57$0.66ViewN/AView Earnings Details
8/4/2011$0.65$0.73ViewN/AView Earnings Details
5/9/2011$0.51$0.56ViewN/AView Earnings Details
2/24/2011$0.45$0.51ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Valeant Pharmaceuticals International (NYSE:VRX)
2017 EPS Consensus Estimate: $3.58
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.94$0.94$0.94
Q2 20171$1.01$1.01$1.01
Q3 20171$0.83$0.83$0.83
Q4 20171$0.80$0.80$0.80
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Valeant Pharmaceuticals International (NYSE:VRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Valeant Pharmaceuticals International (NYSE VRX)

Insider Ownership Percentage: 5.87%
Institutional Ownership Percentage: 46.61%
Insider Trades by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)
Institutional Ownership by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Insider Trades by Quarter for Valeant Pharmaceuticals International (NYSE VRX)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/21/2017Schutter Richard U DeDirectorBuy10,000$14.33$143,300.00View SEC Filing  
5/11/2017Schutter Richard U DeDirectorBuy20,000$13.90$278,000.00View SEC Filing  
3/15/2017Schutter Richard U DeDirectorBuy10,000$10.80$108,000.00View SEC Filing  
3/14/2017Paul HerendeenCFOBuy24,000$10.72$257,280.00View SEC Filing  
3/14/2017Valueact Capital Master Fund,InsiderBuy3,000,000$10.82$32,460,000.00View SEC Filing  
3/13/2017Pershing Square Capital ManageDirectorSell18,114,432$11.00$199,258,752.00View SEC Filing  
12/14/2016Thomas W Sr. RossDirectorBuy5,000$14.73$73,650.00View SEC Filing  
12/12/2016Pershing Square Capital ManageDirectorSell3,476,690$14.85$51,628,846.50View SEC Filing  
8/11/2016Argeris N KarabelasDirectorBuy4,000$24.65$98,600.00View SEC Filing  
6/10/2016Joseph C PapaCEOBuy202,000$24.48$4,944,960.00View SEC Filing  
10/21/2015Ronald Harold FarmerDirectorBuy1,500$181.60$272,400.00View SEC Filing  
7/31/2015Robert L RosielloCFOBuy7,875$254.28$2,002,455.00View SEC Filing  
6/12/2015Robert L RosielloEVPBuy12,900$232.51$2,999,379.00View SEC Filing  
6/9/2015Ronald Harold FarmerDirectorBuy1,000$260.63$260,630.00View SEC Filing  
6/8/2015Ronald Harold FarmerDirectorBuy500$289.20$144,600.00View SEC Filing  
6/2/2015Pavel MirovskyEVPSell38,000$238.01$9,044,380.00View SEC Filing  
5/26/2015Anne Clem WhitakerDirectorBuy7,500$234.67$1,760,025.00View SEC Filing  
5/4/2015Robert Roswell Chai-OnnEVPSell90,938$222.54$20,237,342.52View SEC Filing  
12/10/2014Jeffrey W UbbenInsiderBuy250,000$140.06$35,015,000.00View SEC Filing  
12/3/2014Katharine Berghuis StevensonDirectorBuy1,500$145.73$218,595.00View SEC Filing  
11/24/2014Jeffrey W UbbenInsiderBuy210,000$142.25$29,872,500.00View SEC Filing  
6/23/2014Robert Roswell Chai-OnnEVPSell10,203$121.70$1,241,705.10View SEC Filing  
5/13/2014Robert Roswell Chai-OnnEVPSell10,000$130.08$1,300,800.00View SEC Filing  
4/1/2014Norma Ann ProvencioDirectorSell5,000$132.18$660,900.00View SEC Filing  
3/21/2014Laizer KornwasserEVPBuy2,481$134.97$334,860.57View SEC Filing  
2/3/2014Norma Ann ProvencioDirectorSell5,000$136.23$681,150.00View SEC Filing  
1/24/2014Laizer KornwasserEVPBuy2,536$132.15$335,132.40View SEC Filing  
1/13/2014Norma Ann ProvencioDirectorSell5,000$133.00$665,000.00View SEC Filing  
12/14/2013J. Michael PearsonCEOBuy184,247$81.41$14,999,548.27View SEC Filing  
11/18/2013Laizer KornwasserEVPBuy3,500$107.38$375,830.00View SEC Filing  
11/6/2013Ronald Harold FarmerDirectorBuy1,500$107.98$161,970.00View SEC Filing  
9/13/2013Laizer KornwasserEVPBuy1,000$99.02$99,020.00View SEC Filing  
9/6/2013Norma Ann ProvencioDirectorSell4,000$100.25$401,000.00View SEC Filing  
9/3/2013Norma Ann ProvencioDirectorSell5,000$99.68$498,400.00View SEC Filing  
8/29/2013Fred HassanDirectorBuy51,000$99.01$5,049,510.00View SEC Filing  
8/28/2013Ronald Harold FarmerDirectorBuy2,500$102.36$255,900.00View SEC Filing  
8/23/2013Robert Roswell Chai-OnnEVPBuy5,032$99.30$499,677.60View SEC Filing  
8/12/2013Brian StolzEVPBuy4,500$100.71$453,195.00View SEC Filing  
8/9/2013Laizer KornwasserEVPBuy3,500$100.36$351,260.00View SEC Filing  
6/19/2013G Mason MorfitInsiderBuy1,352,941$85.00$114,999,985.00View SEC Filing  
6/12/2013Lloyd Mitchell SegalDirectorBuy3,190$84.16$268,470.40View SEC Filing  
6/11/2013Norma Ann ProvencioDirectorSell6,000$85.26$511,560.00View SEC Filing  
3/11/2013Laizer KornwasserEVPBuy2,000$70.61$141,220.00View SEC Filing  
11/7/2012Brian M StolzEVPBuy2,040$52.76$107,630.40View SEC Filing  
11/6/2012Howard Bradley SchillerCFOBuy18,300$54.10$990,030.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Valeant Pharmaceuticals International (NYSE VRX)

Source:
DateHeadline
Deutsche Bank AG Analysts Give Valeant Pharmaceuticals International, Inc. (VRX) a $18.00 Price TargetDeutsche Bank AG Analysts Give Valeant Pharmaceuticals International, Inc. (VRX) a $18.00 Price Target
www.americanbankingnews.com - November 18 at 7:34 PM
Valeant: Tempting? Sure. But It Might Not Be a Buy Just Yet.Valeant: Tempting? Sure. But It Might Not Be a Buy Just Yet.
finance.yahoo.com - November 18 at 10:09 AM
Deutsche Bank Pinpoints Uncertainties Nipping at Valeant’s Potential for GrowthDeutsche Bank Pinpoints Uncertainties Nipping at Valeant’s Potential for Growth
finance.yahoo.com - November 18 at 10:09 AM
Valeant (VRX) Announces Pricing of Senior Secured Notes - NasdaqValeant (VRX) Announces Pricing of Senior Secured Notes - Nasdaq
www.nasdaq.com - November 16 at 7:23 AM
Valeant: Where Is The Growth? - Seeking AlphaValeant: Where Is The Growth? - Seeking Alpha
seekingalpha.com - November 16 at 7:23 AM
Valeant Pharmaceuticals International, Inc. (VRX) Sees Significant Growth in Short InterestValeant Pharmaceuticals International, Inc. (VRX) Sees Significant Growth in Short Interest
www.americanbankingnews.com - November 14 at 3:28 AM
Valeant: Salix Growth Might Start To Replace Asset Sales In 2018Valeant: Salix Growth Might Start To Replace Asset Sales In 2018
seekingalpha.com - November 13 at 4:50 PM
Valeant: Is the Rally Over?Valeant: Is the Rally Over?
finance.yahoo.com - November 13 at 4:50 PM
Corporate News Blog - Valeant Pharma Completes Sale of its Obagi Medical Products BusinessCorporate News Blog - Valeant Pharma Completes Sale of its Obagi Medical Products Business
finance.yahoo.com - November 13 at 11:13 AM
Valeant issues $750 million in debt to pay down debtValeant issues $750 million in debt to pay down debt
finance.yahoo.com - November 13 at 11:13 AM
Valeant Pharmaceuticals International, Inc. (VRX) Given New $17.00 Price Target at BMO Capital MarketsValeant Pharmaceuticals International, Inc. (VRX) Given New $17.00 Price Target at BMO Capital Markets
www.americanbankingnews.com - November 13 at 10:49 AM
BRIEF-Valeant completes sale of Obagi Medical products business to Haitong International Zhongua Finance Acquisition Fund I, L.P.BRIEF-Valeant completes sale of Obagi Medical products business to Haitong International Zhongua Finance Acquisition Fund I, L.P.
finance.yahoo.com - November 12 at 1:14 PM
Valeant Pharma: Why This Bear Still GrowlsValeant Pharma: Why This Bear Still Growls
finance.yahoo.com - November 12 at 1:14 PM
Valeant on the Mend? H.C. Wainwright Remains on the Sidelines Until Pipeline Strength Proves Itself a Gains MakerValeant on the Mend? H.C. Wainwright Remains on the Sidelines Until Pipeline Strength Proves Itself a Gains Maker
finance.yahoo.com - November 12 at 1:14 PM
Valeant Pharmaceuticals International, Inc. (VRX) Receives "Sell" Rating from Piper Jaffray CompaniesValeant Pharmaceuticals International, Inc. (VRX) Receives "Sell" Rating from Piper Jaffray Companies
www.americanbankingnews.com - November 11 at 9:42 AM
Valeant: 11 Months Later: The Countdown Continues - Seeking AlphaValeant: 11 Months Later: The Countdown Continues - Seeking Alpha
seekingalpha.com - November 9 at 9:39 AM
Valeant: A Humble But Crafty Deal - Seeking AlphaValeant: A Humble But Crafty Deal - Seeking Alpha
seekingalpha.com - November 9 at 9:39 AM
Valeant Pharmaceuticals (VRX) in Focus: Stock Moves 5.5% HigherValeant Pharmaceuticals (VRX) in Focus: Stock Moves 5.5% Higher
finance.yahoo.com - November 9 at 9:39 AM
Valeant Pharmaceuticals Internationals (VRX) Hold Rating Reaffirmed at Deutsche Bank AGValeant Pharmaceuticals International's (VRX) Hold Rating Reaffirmed at Deutsche Bank AG
www.americanbankingnews.com - November 8 at 10:26 PM
Valeant Pharmaceuticals International, Inc. (VRX) PT Set at $18.00 by Royal Bank Of CanadaValeant Pharmaceuticals International, Inc. (VRX) PT Set at $18.00 by Royal Bank Of Canada
www.americanbankingnews.com - November 8 at 3:10 PM
Valeant shares surge 12% after Q3 revenue beat - MarketWatchValeant shares surge 12% after Q3 revenue beat - MarketWatch
www.marketwatch.com - November 7 at 11:30 PM
Earnings Reaction History: Valeant Pharmaceuticals International ... - NasdaqEarnings Reaction History: Valeant Pharmaceuticals International ... - Nasdaq
www.nasdaq.com - November 7 at 6:28 PM
Valeant shares rise on divestiture of female Viagra - MarketWatchValeant shares rise on divestiture of 'female Viagra' - MarketWatch
www.marketwatch.com - November 7 at 6:28 PM
Pre-Market Most Active for Nov 7, 2017 : VRX, NOK, TEVA, DCIX, DB, SAP, TLGT, AAPL, TRIP, BABA, TVIX, QQQ - NasdaqPre-Market Most Active for Nov 7, 2017 : VRX, NOK, TEVA, DCIX, DB, SAP, TLGT, AAPL, TRIP, BABA, TVIX, QQQ - Nasdaq
www.nasdaq.com - November 7 at 6:28 PM
Valeant: Vyzulta Approval Actually Big News - Seeking AlphaValeant: Vyzulta Approval Actually Big News - Seeking Alpha
seekingalpha.com - November 7 at 6:28 PM
Will Valeants $1 Billion Headache Metastasize? - Seeking AlphaWill Valeant's $1 Billion Headache Metastasize? - Seeking Alpha
seekingalpha.com - November 7 at 6:28 PM
Valeant Pharmaceuticals International, Inc. (VRX) Upgraded at TD SecuritiesValeant Pharmaceuticals International, Inc. (VRX) Upgraded at TD Securities
www.americanbankingnews.com - November 7 at 4:36 PM
Top 3 Companies Owned by Valeant (VRX)Top 3 Companies Owned by Valeant (VRX)
finance.yahoo.com - November 7 at 1:21 PM
Valeant Agrees To Sell Sprout Pharmaceuticals Subsidiary To Former Shareholders Of Sprout PharmaceuticalsValeant Agrees To Sell Sprout Pharmaceuticals Subsidiary To Former Shareholders Of Sprout Pharmaceuticals
finance.yahoo.com - November 6 at 9:00 AM
Todays Research Reports on Stocks to Watch: Valeant Pharmaceuticals and HerbalifeToday's Research Reports on Stocks to Watch: Valeant Pharmaceuticals and Herbalife
finance.yahoo.com - November 6 at 9:00 AM
Valeant Pharmaceuticals International, Inc. (VRX) Expected to Post Quarterly Sales of $2.17 BillionValeant Pharmaceuticals International, Inc. (VRX) Expected to Post Quarterly Sales of $2.17 Billion
www.americanbankingnews.com - November 5 at 4:30 AM
Dow aims for fresh record as stock futures climb ahead of U.S. jobs reportDow aims for fresh record as stock futures climb ahead of U.S. jobs report
finance.yahoo.com - November 5 at 1:44 AM
Valeant Pharmaceuticals Internationals (VRX) "Hold" Rating Reiterated at HC WainwrightValeant Pharmaceuticals International's (VRX) "Hold" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - November 4 at 11:32 PM
TD Securities Reiterates "Hold" Rating for Valeant Pharmaceuticals International, Inc. (VRX)TD Securities Reiterates "Hold" Rating for Valeant Pharmaceuticals International, Inc. (VRX)
www.americanbankingnews.com - November 4 at 1:32 PM
Valeant Pharma (VRX) Confirms FDA Approval Of VYZULTA - StreetInsider.comValeant Pharma (VRX) Confirms FDA Approval Of VYZULTA - StreetInsider.com
www.streetinsider.com - November 4 at 6:18 AM
Valeant Surrenders Some Early Gains After FDA Approval Of VYZULTA - BenzingaValeant Surrenders Some Early Gains After FDA Approval Of VYZULTA - Benzinga
www.benzinga.com - November 4 at 6:18 AM
Valeant Pharmaceuticals International, Inc. (VRX) Expected to Post Earnings of $0.91 Per ShareValeant Pharmaceuticals International, Inc. (VRX) Expected to Post Earnings of $0.91 Per Share
www.americanbankingnews.com - November 3 at 9:12 PM
Stock Futures Hold Higher After U.S. Adds 261,000 in OctoberStock Futures Hold Higher After U.S. Adds 261,000 in October
www.thestreet.com - November 3 at 9:53 AM
Valeants Glaucoma Drug Wins FDA ApprovalValeant's Glaucoma Drug Wins FDA Approval
finance.yahoo.com - November 3 at 9:53 AM
Morning Movers: Valeant Climbs, Sears Sinks, Herbalife DropsMorning Movers: Valeant Climbs, Sears Sinks, Herbalife Drops
finance.yahoo.com - November 3 at 9:53 AM
Dow aims for fresh record as stock futures climb after U.S. jobs reportDow aims for fresh record as stock futures climb after U.S. jobs report
finance.yahoo.com - November 3 at 9:53 AM
Valeant Pharmaceuticals Stock Jump on FDA Approval of Glaucoma TreatmentValeant Pharmaceuticals Stock Jump on FDA Approval of Glaucoma Treatment
finance.yahoo.com - November 3 at 9:53 AM
Nicox Highlights VYZULTATM approval, Latest Corporate and Financial Developments, and Upcoming Pipeline InitiativesNicox Highlights VYZULTATM approval, Latest Corporate and Financial Developments, and Upcoming Pipeline Initiatives
feeds.benzinga.com - November 3 at 2:58 AM
Any Way You Slice It: Is Valeant a Safer Bet Following Debt Offering, Asset Sales?Any Way You Slice It: Is Valeant a Safer Bet Following Debt Offering, Asset Sales?
finance.yahoo.com - November 1 at 10:37 AM
Valeant Will Reduce Debt By Additional $125 MillionValeant Will Reduce Debt By Additional $125 Million
finance.yahoo.com - November 1 at 10:37 AM
Valeant Pharmaceuticals International, Inc. (VRX) Receives Average Recommendation of "Hold" from AnalystsValeant Pharmaceuticals International, Inc. (VRX) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - November 1 at 1:34 AM
Valeant Pharmaceuticals International, Inc. (VRX) Rating Reiterated by BMO Capital MarketsValeant Pharmaceuticals International, Inc. (VRX) Rating Reiterated by BMO Capital Markets
www.americanbankingnews.com - October 30 at 4:36 PM
PDL BioPharma (PDLI) Announces Settlement Agreement with Valeant (VRX) - StreetInsider.comPDL BioPharma (PDLI) Announces Settlement Agreement with Valeant (VRX) - StreetInsider.com
www.streetinsider.com - October 30 at 8:25 AM
Will Asset Impairments Finally Trip Valeant? - Seeking AlphaWill Asset Impairments Finally Trip Valeant? - Seeking Alpha
seekingalpha.com - October 30 at 8:25 AM
Valeant Pharmaceuticals International, Inc. (VRX) Given "Sell" Rating at Wells Fargo & CompanyValeant Pharmaceuticals International, Inc. (VRX) Given "Sell" Rating at Wells Fargo & Company
www.americanbankingnews.com - October 28 at 11:10 AM

Social Media

Financials

Chart

Valeant Pharmaceuticals International (NYSE VRX) Chart for Sunday, November, 19, 2017
Loading chart…

This page was last updated on 11/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.